Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer

Exelixis (Nasdaq: EXEL) announced positive topline results from its pivotal Phase 3 STELLAR-303 trial, demonstrating that zanzalintinib in combination with atezolizumab achieved a statistically significant improvement in overall survival (OS) compared to regorafenib in the intent-to-treat population of patients with previously treated non-microsatellite instability-high metastatic colorectal cancer. This outcome, consistent with known safety profiles, marks a crucial first milestone for Exelixis' zanzalintinib development program, with the company planning discussions with regulatory authorities and detailed data presentation at an upcoming medical conference, signaling potential for a new therapeutic option in this indication.

Analysis

Exelixis has reported a significant clinical and strategic success with positive topline results from its STELLAR-303 pivotal Phase 3 trial. The combination of zanzalintinib and atezolizumab demonstrated a statistically significant improvement in overall survival (OS) versus the comparator, regorafenib, in the intent-to-treat population of patients with non-MSI-high metastatic colorectal cancer (CRC). This outcome represents a major de-risking event for zanzalintinib, a key pipeline asset intended to expand upon the company's flagship cabozantinib franchise. The achievement of this primary endpoint in a difficult-to-treat population, coupled with a consistent safety profile and no new safety signals, strongly supports the therapeutic potential of the combination. While the trial will proceed to its second dual primary endpoint analysis for patients without liver metastases, successfully meeting the endpoint in the broader ITT population provides a robust foundation for planned regulatory discussions and a potential New Drug Application. This result positions Exelixis to address a significant unmet need in CRC, a market characterized by poor survival rates in the metastatic setting.

Key Decisions for Investors

• The positive Phase 3 data materially de-risks the zanzalintinib program, strengthening Exelixis's long-term growth pipeline and justifying a potential upward re-rating of the company's valuation.
• Investors should closely monitor near-term catalysts, including the detailed data presentation at an upcoming medical conference and the results of the second primary endpoint, as these will further define the drug's clinical profile and commercial opportunity.
• The planned engagement with regulatory authorities is the next critical milestone; any formal update on the submission timeline for a New Drug Application will likely serve as a significant share price driver.
• Consider this a pivotal development that enhances the company's competitive positioning in oncology, but maintain awareness that ultimate approval and market adoption are still subject to regulatory review and further data readouts.